Incyte reports positive data from Phase I/II combination trial for melanoma

Incyte has reported additional positive data from a Phase I/II clinical trial (ECHO-202) of its product candidate epacadostat in combination with Merck ’s anti-PD-1 drug Keytruda (pembrolizumab) to treat advanced melanoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news